Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Sept 2024
- Ended
- Jul 2025
- Type of study
- Observational
- Treatments tested
- Wearable Sensors
- Record updated
- 25 September 2024
- Why it stopped
- The study was activated at the onset of the COVID pandemic. At that time voluntary, non-therapeutic research was placed on hold. Now the technology has evolved and have elected to forego this protocol.
Who can take part
- Age
- 5 years to 25 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Between 5 and 25 years of age at time of study enrollment
- Undergoing induction therapy for acute lymphoblastic leukemia at St. Jude
- Expected to remain outpatient during periods of high infection risk
Who cannot take part
- Documented allergy to components of the device (Empatica E4: elemental silver, polyurethane, or polycarbonate; TempTraq: latex-free adhesive)
- Any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
- Current fever or sepsis at time of enrollment
Where in United States
- St. Jude Children's Research HospitalMemphis, United States
About the trial
What the trial wants to find out
Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood and long-term survival has risen to above 90%, but 1-4% of treated patients die from infections. Early detection and treatment of infection can improve these outcomes by preventing increased severity and death. This study aims to determine whether continuous analysis of information from wearable devices (Like a watch and sticky patch) that measure temperature, pulse rate, oxygen level, and other similar information can predict infection before it is apparent to the patient or caregiver. About 65 patients will be enrolled and will wear these devices for 10 days; during that time the information will be recorded, but not available. After completion, information collected immediately before infection will be compared to other times to identify features that predict infections.
The group in the trial
- Participants
Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
Treatment: Wearable Sensors
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 September 2024